Cancer Research Response to Reviewers: AACR Revision Guide

Cancer manuscripts often use the word "mechanism" for evidence at very different levels. Classify the revised claim before deciding how to respond.

A reviewer asking for mechanism may be asking for one missing rung, not an unlimited experiment list. State which rung the new evidence reaches and update the language accordingly.

Create a model inventory for every key result:

1. cell line, organoid, patient-derived xenograft, genetically engineered model, cohort, or trial sample;
2. biological replicate and technical replicate definition;
3. inclusion and exclusion rules;
4. treatment, time point, dose, and comparator;
5. primary and exploratory outcomes;
6. missing observations and failed experiments;
7. statistical unit and model;
8. disease, subtype, and treatment context supported.

This inventory catches a common revision contradiction: a broader validation model is added to one figure, but the abstract still generalizes across cancers, stages, or therapies that were never tested.

AACR's acceptance process includes legal, research-reporting, and formatting requirements after the scientific concerns are addressed. Do not wait for provisional acceptance to discover that the revision cannot support an image or dataset.

For each revised display item, verify:

A response that adds a visually compelling panel without an auditable evidence trail can increase rather than reduce re-review risk.

Differentiate reviewer comments and author responses with bold labels, boxes, or indentation. Do not rely on color. Keep editor issues, reviewer text, quoted revised language, and author explanations visually separate.

If you upload a marked-text manuscript, use markup consistently and confirm that the clean source file contains the same scientific content. Figures may not sit inside the main text file under AACR's current revised-submission process, so verify panel labels and legends across uploaded files.

Concede the evidence level precisely. Push back by explaining why a requested test would not identify the proposed causal or translational question.

In our pre-submission review work with Cancer Research manuscripts, we audit the causal logic, model systems, experimental units, statistics, figures, source data, ethics and reporting statements, omics pipelines, abstracts, and translational claims. We map each reviewer comment to an evidence level and trace every changed conclusion through the revised panels and source files. These are qualitative Manusights patterns, not Cancer Research acceptance rates or confidential editorial access.

Pattern 1: one perturbation is labeled a mechanism

Knockdown changes tumor growth or treatment response, and the revised manuscript adds another endpoint from the same perturbation. In Cancer Research revisions, we inspect off-target control, rescue, temporal order, downstream specificity, and parallel pathways. The correct revised claim may be contribution rather than sole mechanism. We see the same gap when pharmacologic inhibition and genetic loss are treated as independent despite converging on one unverified pathway assumption.

Pattern 2: validation repeats the same biological limitation

The response adds a second established cell line with the same lineage bias, genotype, culture condition, or assay artifact. For Cancer Research manuscripts, we choose an orthogonal model that challenges the uncertainty: patient-derived material, primary cells, an in vivo context, or a model with the predicted boundary. We audit the model table before accepting a larger sample count as broader validation.

Pattern 3: technical replicates inflate biological certainty

Wells, fields, images, or repeated time points are treated as independent samples. We reconstruct the hierarchy and reanalyze at the biological unit. The result can remain important while the interval widens and a secondary claim disappears.

Pattern 4: translational relevance is added only in prose

The Discussion gains a paragraph about patients, but the tested model, biomarker definition, comparator, and endpoint do not map to a clinical decision. We write a translation ledger: who, when, what intervention, what comparator, what measurable benefit, and what validation remains.

The distinctive Cancer Research information gain is evidence-level alignment: perturbation, model, statistical unit, source data, and translational language must support the same cancer claim.

Check the Cancer Research response and revised evidence together.

One reviewer may request a broader mechanism while another asks for tighter clinical framing. Summarize the tension for the editor. A mechanistic experiment and a human association answer different questions. Keep both only when the manuscript labels the boundary between them.

If reviewers request mutually incompatible models or endpoints, identify which test is decisive for the editor's stated concern. Do not quietly satisfy each comment with contradictory versions of the central claim.

Revision is not acceptance. Most serious rejection-on-revision risks include an associative mechanism that remains overstated, validation in a non-discriminating model, pseudoreplication, selective endpoints, untraceable image evidence, and translational language unsupported by the studied population or intervention.

Most dangerous is a formally complete point-by-point response whose new experiments do not change the evidence level.

We reviewed current Cancer Research and AACR author materials, AACR's editorial process for revised submissions, article style and reporting policies, then applied the mechanism-evidence audit above. AACR sources establish the point-by-point and change-location requirements. The evidence ladder and model inventory are Manusights analysis.

This page is for the AACR journal Cancer Research, not the broad topic or another similarly named journal. It does not predict acceptance or replace the actual decision letter and submission task list.

1. Put handling-editor priorities before reviewer sections.
2. Reproduce and answer every comment and subpart.
3. List all changes with page, line, figure, panel, table, and supplement locations.
4. Match mechanistic language to the evidence ladder.
5. Use models that challenge, not repeat, the key uncertainty.
6. Reconcile biological units, exclusions, missingness, and multiplicity.
7. Verify images, source data, accessions, code, ethics, and reporting items.
8. State negative, partial, and model-specific results.
9. Synchronize response, clean files, displays, abstract, and discussion.
10. Keep reviewer and author text visually distinct.

After indexation, wait for 14 final Search Console days before interpreting movement. At 21 days, decide whether this AACR owner should remain, change, merge, or stop by checking exact-query ownership, impressions, clicks, rank, and qualified starts. The source cluster had 12,329 impressions and one preview start; neither proves demand for this exact page.

AACR sources establish the revision file and reporting requirements. The cancer evidence ladder is Manusights interpretation.